JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 3 filers reported holding JUNO THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $66,000 | +61.0% | 1,435 | +4.2% | 0.00% | – |
| Q2 2017 | $41,000 | +28.1% | 1,377 | -5.1% | 0.00% | – |
| Q1 2017 | $32,000 | +10.3% | 1,451 | -4.5% | 0.00% | – |
| Q4 2016 | $29,000 | -99.9% | 1,519 | -0.6% | 0.00% | – |
| Q3 2016 | $45,855,000 | -25.5% | 1,528 | -4.6% | 0.00% | – |
| Q2 2016 | $61,581,000 | -38.4% | 1,602 | -39.1% | 0.00% | – |
| Q1 2016 | $100,000,000 | -54.8% | 2,631 | -47.7% | 0.00% | -100.0% |
| Q4 2015 | $221,000,000 | +19544.4% | 5,026 | -81.8% | 0.00% | -80.0% |
| Q3 2015 | $1,125,000 | -99.7% | 27,638 | +306.0% | 0.01% | +400.0% |
| Q2 2015 | $363,071,000 | +59.3% | 6,808 | +81.2% | 0.00% | 0.0% |
| Q1 2015 | $227,960,000 | +0.5% | 3,758 | -13.5% | 0.00% | 0.0% |
| Q4 2014 | $226,896,000 | – | 4,345 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Biomark Capital Management Co. LLC | 2,168,601 | $65,080,000 | 86.12% |
| Crestline Management, LP | 17,348,799 | $520,637,000 | 66.02% |
| Omega Fund Management, LLC | 1,229,512 | $36,898,000 | 28.17% |
| SIB LLC | 100,000 | $3,001,000 | 2.42% |
| Clarius Group, LLC | 117,896 | $3,538,000 | 1.65% |
| BB BIOTECH AG | 1,405,000 | $42,164,000 | 1.48% |
| Duquesne Family Office | 493,000 | $14,795,000 | 1.31% |
| First Washington CORP | 65,320 | $1,960,000 | 1.10% |
| PFM Health Sciences, LP | 1,124,285 | $33,740,000 | 0.99% |
| Partner Investment Management, L.P. | 18,376 | $551,000 | 0.82% |